Baseline demographic and clinical characteristics of patients (N=77)
| Characteristics | n (%) |
| Median age at IMDC onset, years (IQR) | 62 (52–71) |
| Male | 51 (66) |
| White | 72 (94) |
| Cancer type | |
| Genitourinary cancer | 35 (44) |
| Melanoma | 17 (22) |
| Lung cancer | 11 (14) |
| Others* | 14 (18) |
| Cancer stage | |
| Stage III | 13 (17) |
| Stage IV | 64 (83) |
| Checkpoint inhibitor type | |
| CTLA-4 | 13 (17) |
| PD-1/L1 | 37 (48) |
| Combination | 27 (35) |
| Median duration from first FC test at IMDC onset to last FC test after treatment, months (IQR) | 9 (8–13) |
| Median follow-up duration, months (IQR) | 15 (11–26) |
| Death, any cause | 20 (26) |
Cause of death is due to cancer progression in all 20 patients.
*Gastrointestinal/hepatobiliary cancer (n=5), head and neck/endocrine cancer (n=4), breast cancer (n=2), cervical cancer (n=2) and sarcoma (n=1).
CTLA-4, cytotoxic T lymphocyte antigen-4; FC, fecal calprotectin; IMDC, immune-mediated diarrhea and colitis; PD-1/L1, programmed death-1/programmed death-1 ligand.